Olsalazine Versus Sulfasalazine in Mild to Moderate Childhood Ulcerative Colitis

Ferry, George D.; Kirschner, Barbara S.; Grand, Richard J.; Issenman, Robert M.; Griffiths, Anne M.; Vanderhoof, John; Fiedorek, Stephen C.; Winter, Harland S.; Hassall, Eric; Watkins, John B.; Gryboski, Joyce D.; Ulshen, Martin H.; Daum, Frederic; Perman, Jay A.; Thomas, D. Winton; Heubi, James E.; Byrne, William J.; Jones, Bobbette A.

doi:10.1097/00005176-199307000-00005

Cited by 66 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the recent meta-analysis showed no difference for both inducing and maintaining remission (57). One pediatric double-blinded randomized clinical trial (RCT) showed that olsalazine 30 mg Á kg À1 Á day À1 induced clinical response in 39% versus 79% with sulfasalazine 60 mg Á kg À1 Á day À1 after 3 months in 56 children with mild to moderate UC (61). Results from another pediatric trial suggested equivalent efficacy of mesalazine and sulfasalazine in maintaining remission in either UC or Crohn colitis (64).…”

Section: Medical Managementmentioning

confidence: 99%

Management of Pediatric Ulcerative Colitis

Turner

Levine

Escher

et al. 2012

J. pediatr. gastroenterol. nutr.

Self Cite

329

105

View full text Add to dashboard Cite

show abstract

Section: Medical Managementmentioning

confidence: 99%

Management of Pediatric Ulcerative Colitis

Turner

Levine

Escher

et al. 2012

J. pediatr. gastroenterol. nutr.

Self Cite

329

105

View full text Add to dashboard Cite

show abstract

“…Another study reported on the safety and efficacy of olsalazine sodium and SASP in 56 children with mild to moderate UC. Some patients belonging to the olsalazine group improved, and some showed a progression of symptoms compared with the SASP group [44]. Furthermore, SASP was selected as the positive drug on the basis of the reported studies evaluating its therapeutic effects on UC [45][46][47].…”

Section: Discussionmentioning

confidence: 99%

Improvement of Oxazolone-Induced Ulcerative Colitis in Rats Using Andrographolide

et al. 2019

View full text Add to dashboard Cite

Ulcerative colitis (UC) is usually accompanied with symptoms of abdominal pain, diarrhea, and bloody stool, which impair the quality of life of patients. Previous studies have shown that Andrographis paniculata extracts, which have andrographolide (AND) as their main compound, can relieve UC symptoms in patients. The aim of the study was to investigate the alleviating effect of AND on UC using the oxazolone (OXZ)-induced UC rat model. A total of 66 healthy male Sprague Dawley rats were used to evaluate the efficacy and mechanism of AND on UC (n = 11 per group) and grouped into control, model, SASP (sulfasalazine, positive control group, 500 mg/kg), AND-L (40 mg/kg), AND-M (80 mg/kg), and AND-H (120 mg/kg). The colonic disease activity index (DAI), colon length, spleen coefficient, pathological damage, and inflammation-related cytokine and protein expression levels were used as indices for evaluation. Results showed that the AND groups had reduced DAI and mortality, and significantly improved colon length and spleen coefficient compared with the model group. Furthermore, OXZ-induced histological injury was relieved significantly after AND treatment due to an improved crypt structure and reduced infiltration of inflammatory cells. Moreover, AND inhibited myeloperoxidase (MPO) activity and the secretion of interleukin-4 (IL-4), IL-13, and tumor necrosis factor α (TNF-α). The results of the anti-inflammatory mechanism revealed that AND blocked the signal transduction by reducing IL-4/IL-13 specific binding to IL-4 receptor (IL-4R) and inhibiting the phosphorylation of the signal transducer and activator of transcription 6 (p-STAT6). In conclusion, aside from natural plants, AND may be a candidate ingredient for UC therapy.

show abstract

“…In tests completindication, [17] and it is clinically efficacious in ≈ 80% of pediatric ed in adults, balsalazide appears to be effective in up to 30% of and adult patients. [16,18] Sulfasalazine utilizes a diazo bond to link patients unresponsive to other mesalamine-containing therapies, the topical anti-inflammatory agent 5-aminosalicylate and it may be better tolerated. [19,20] A wide variety of 5-aminosali-(mesalamine) to the inert carrier, sulfapyridine.…”

Section: Ulcerative Colitis (Uc)mentioning

confidence: 99%

“…[18,55,56] As such, pediatric physicians have been using these agents for some time in increase the therapeutic window for the use of these important the management of their patients. [57] Dosing for these medications immunomodulatory agents.…”

Section: Regional Disease In Ucmentioning

confidence: 99%

“…Only 39% of patients receiving olsalazine were clinically blinded and placebo-controlled study evaluating 131 patients ranimproved after 3 months of therapy, compared with 79% of domized to receive mercaptopurine (50 mg/day), mesalamine (3 g/ patients receiving sulfasalazine. [18] day), or placebo after surgery. Clinical recurrence rates at 24 The newest 5-aminosalicylate agent, balsalazide (Colazal ® ), months were 50%, 58%, and 77%, respectively.…”

Section: Postoperative Recurrence Of CDmentioning

confidence: 99%

See 1 more Smart Citation

Current Therapy of Inflammatory Bowel Disease in Children

Rufo

Bousvaros

2006

Pediatric Drugs

View full text Add to dashboard Cite

Ulcerative colitis (UC) and Crohn disease (CD) are chronic intestinal inflammatory diseases that can present as bloody diarrhea, abdominal pain, and malnutrition. Collectively, these disorders are referred to as inflammatory bowel disease (IBD). All patients with IBD share a common pathophysiology. However, there are a number of developmental, psychosocial, and physiologic issues that are unique to the approximate, equals 20% of patients that present during childhood or adolescence. These include the possibility of disease-induced delays in linear growth or physical development, differences in drug dosing, and the changes in social and cognitive development that occur as children move from school-age years into adolescence and early adulthood. Gastroenterologists caring for these children must therefore develop an optimal regimen of pharmacologic therapies, nutritional management, psychologic support, and properly timed surgery (when necessary) that will maintain disease remission, minimize disease and drug-induced adverse effects, and optimize growth and development. This article reviews current approaches to the management of patients with UC and CD and highlights issues specific to the treatment of children with IBD. The principal medical therapies used to induce disease remission in patients with UC are aminosalicylates (for mild disease), corticosteroids (for moderate disease), and cyclosporine (ciclosporin) (for severe disease). If a patient responds to the induction regimen, maintenance therapies that are used to prevent disease relapse include aminosalicylates, mercaptopurine, and azathioprine. Colectomy with creation of an ileal pouch anal anastomosis (J pouch) has become the standard of care for patients with severe or refractory colitis and results in an improved quality of life in most patients. Therefore, the risks associated with using increasingly potent immunosuppressant agents must be balanced in each case against a patient's desire to retain their colon and avoid a temporary or potentially permanent ileostomy. Decisions about drug therapy in the management of patients with CD are more complex and depend on both the location (e.g. gastroduodenal vs small intestinal vs colonic), as well as the behavior of the disease (inflammatory/mucosal vs stricturing vs perforating) in a given patient. Induction therapies for CD typically include aminosalicylates and antibiotics (for mild mucosal disease), nutritional therapy (including elemental or polymeric formulas), corticosteroids (for moderate disease), and infliximab (for corticosteroid-resistant or fistulizing disease). Aminosalicylates, mercaptopurine, azathioprine, methotrexate, and infliximab can be used as maintenance therapies. Because surgical treatment of CD is not curative, it is typically reserved for those patients either with persistent symptoms and disease limited to a small section of the intestine (e.g. the terminal ileum and cecum) or for the management of complications of the disease including stricture or abdominal abscess. When surgery...

show abstract

Olsalazine Versus Sulfasalazine in Mild to Moderate Childhood Ulcerative Colitis

Cited by 66 publications

References 0 publications

Management of Pediatric Ulcerative Colitis

Management of Pediatric Ulcerative Colitis

Improvement of Oxazolone-Induced Ulcerative Colitis in Rats Using Andrographolide

Current Therapy of Inflammatory Bowel Disease in Children

Contact Info

Product

Resources

About